^
    Apply
    Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors (NCT06128551)
    Phase 1
    Revolution Medicines, Inc.
    Recruiting
    Last update posted :
    06/17/2024
    Initiation :
    11/14/2023
    Primary completion :
    11/30/2026
    Completion :
    11/30/2026
    KRAS
    |
    daraxonrasib (RMC-6236) • elironrasib (RMC-6291)
    Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors (NCT05462717)
    Phase 1
    Revolution Medicines, Inc.
    Recruiting
    Last update posted :
    04/19/2024
    Initiation :
    09/19/2022
    Primary completion :
    11/01/2024
    Completion :
    12/01/2025
    KRAS
    |
    KRAS G12C
    |
    elironrasib (RMC-6291)